Brief: Avidity Reports Positive Phase 1/2 Data For Del-Brax In FSHD Patients
09/06/2025 12:21
June 9 (Reuters) - Avidity Biosciences Inc RNA.O: AVIDITY BIOSCIENCES ANNOUNCES POSITIVE TOPLINE PHASE 1/2 FORTITUDE™ DATA DEMONSTRATING CONSISTENT IMPROVEMENT ACROSS MULTIPLE FUNCTIONAL MEASURES COMPARED TO PLACEBO IN DEL-BRAX TREATED FSHD PARTICIPANTS AVIDITY BIOSCIENCES INC - DATA SUPPORT PLANNED ACCELERATED APPROVAL BLA SUBMISSION IN H2 2026 Source text: ID:nPn4d9Kyra Further company coverage: RNA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Avidity Biosciences
See all newsFactbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
Factbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
Brief: Avidity Biosciences Says Record Date Set For February 12, 2026 For Spin-Off